 In the mid-1990s the US FDA approved dexfenfluramine as a weight loss drug.After several reports of adverse cardiovascular effects, the FDA banned dexfenfluramine in 1997.It appears that the 5-HT2B receptors, expressed in cardiac valves, are responsible for the valvulopathies reported from the use of fenfluramine and dexfenfluramine.